Abstract:Accurate detection of circulating tumor DNA (ctDNA) has the potential to guide personalized cancer therapy. DNA viruses such as Epstein-Barr virus (EBV) and human papillomavirus (HPV) are major oncologic drivers of nasopharyngeal cancer (NPC) and cervical cancer (CC), respectively, and provide a convenient etiological marker for measurement of ctDNA. Polymerase chain reaction (PCR)-based methods have been widely studied, but more accurate tests are needed. We hypothesized that a next generation sequencing (NGS) approach could outperform PCR-based methods for viral ctDNA detection. We developed a novel NGS method for viral ctDNA detection. Viral genome sequencing for EBV (EBV-seq) or HPV (HPV-seq) was achieved by hybrid capture NGS. Unique molecular identifiers were incorporated for accurate copy number quantification. We implemented a custom bioinformatics workflow to (1) quantify viral sequences, (2) report viral subtype, and (3) measure ctDNA fragment length. The lower limit of detection (LLOD) was compared with published PCR-based methods in cell line dilution series. To test performance on clinical samples, we applied EBV-seq to a cohort of 19 newly diagnosed EBV-associated NPC patients for whom the clinical EBV quantitative PCR test had provided a false negative result and to a control cohort of 20 healthy volunteers. We applied HPV-seq to 40 plasma samples from a cohort of 18 CC patients treated with chemoradiotherapy and to a control cohort of 5 healthy volunteers. The LLOD of EBV-Seq was ≤0.01 EBV genome-equivalents (GE), 100X lower than quantitative PCR. The LLOD of HPV-seq was ≤0.2 HPV GE, 10X lower than digital PCR. For EBV-seq, 19/19 NPC patients had detectable ctDNA (sensitivity=100%, range=0.08-141 EBV GE); 10/20 controls had detectable ctDNA (specificity=50%, range=0.02-0.71 EBV GE). 17/19 (89%) patients, including 6/6 with stage I-II disease, had EBV-seq levels that were >20X above the highest level seen in the control cohort (i.e., 89% sensitivity with 100% specificity). For HPV-seq, 6/6 baseline CC samples, 10/17 (59%) end-of-treatment samples, 1/14 (7%) 3-month post-treatment samples, and 3/3 samples taken upon recurrence had positive HPV-seq results (sensitivity=100%, range=0.02-559 HPV GE) that were highly correlated with digital PCR (Pearson R=0.97) but with 60X higher signal than digital PCR; 0/5 controls had detectable ctDNA (specificity=100%). EBV-seq and HPV-seq were able to report viral subtype in 49/49 positive samples. Viral ctDNA was consistently shorter than non-cancer-derived plasma DNA (median difference=15bp). For DNA virus-associated cancers, viral genome NGS provides dramatically greater sensitivity than PCR-based methods and enables viral subtyping and ctDNA fragment length analysis. Further evaluation is warranted to test the clinical utility of ultrasensitive ctDNA detection using this approach.

Comparison of Real-Time PCR and Digital PCR for Detection of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma

Comparing BamHI-W and CE-marked assays to detect circulating Epstein-Barr Virus (EBV) DNA of nasopharyngeal cancer patients in a non-endemic area

CRISPR Cas12a-mediated Amplification-Free Digital DNA Assay Improves the Diagnosis and Surveillance of Nasopharyngeal Carcinoma.

Quantification of low-level Cytomegalovirus and Epstein-Barr virus DNAemia by digital PCR

Quantitative Analysis of Epstein-Barr Virus DNA in Plasma and Peripheral Blood Cells in Patients with Nasopharyngeal Carcinoma

Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas

Comparison of Epstein-Barr Virus Dna Level in Plasma, Peripheral Blood Cell and Tumor Tissue in Nasopharyngeal Carcinoma

Evaluation of Performance and Application of Three Nucleic Acid Extraction Methods for Quantification of Plasma Epstein-Barr Virus DNA

Viral Genome Sequencing for Ultrasensitive Detection of Circulating Tumor DNA

Advantages of Digital PCR in the Detection of Low Abundance BCR-ABL1 Gene in Patients with Chronic Myeloid Leukemia

Performance and Operational Feasibility of Epstein-Barr Virus–Based Screening for Detection of Nasopharyngeal Carcinoma: Direct Comparison of Two Alternative Approaches

Evaluation of Plasma Epstein‐Barr Virus DNA Load to Distinguish Nasopharyngeal Carcinoma Patients from Healthy High‐risk Populations in Southern China

Comparison of Plasma Epstein-Barr Virus (ebv) Dna Levels and Serum Ebv Immunoglobulin A/Virus Capsid Antigen Antibody Titers in Patients with Nasopharyngeal Carcinoma

The Clinical Utility of Plasma Epstein–Barr Virus DNA Assays in Nasopharyngeal Carcinoma

Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinoma

Expression of Epstein-Barr Virus DNA in Peripheral Blood Lymphocytes and Plasma in Patients with EBV-Associated Diseases

Clinical Relevance of Plasma EBV DNA As a Biomarker for Nasopharyngeal Carcinoma in Non-Endemic Areas: A Multicenter Study in Southwestern China

Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma

[Significance of Cell-Free Epstein-Barr Virus DNA in Monitoring Prognosis of Nasopharyngeal Carcinoma].

[Real-Time Quantitative PCR Assay of Epstein-Barr Virus in Whole Blood Cells of Nasopharyngeal Carcinoma Patients].

Utility of Epstein–Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs